BIOGEN INC. (BIIB) Form 10-Q — Oct 28, 2026
Biogen reported Q3 2026 total revenue of $2.8 billion, up 10.6% from $2.5 billion a year ago, driven by new products including SYFOVRE and EMPAVELI from the May 2026 Apellis acquisition plus continued ZURZUVAE and LEQEMBI growth. Despite the top-line growth, Biogen swung to a Q3 net loss of $20.6 million (EPS of -$0.14) versus net income of $466.5 million ($3.18 EPS) in Q3 2025, driven by $283.8 million of acquired IPR&D/milestone expense, $66.5 million of restructuring charges, and higher SG&A and inventory step-up amortization.
Key figures
- Revenue
- 2804.1
- Revenue Yoy
- 10.6% (Q3: $2,804.1M vs $2,534.7M)
- Cash Position
- 1303.9
- Shares Outstanding
- 147820223
- Q3 r and d
- 574.0M
- Q3 2025 eps
- 3.18
- Tj bio upfront
- 100.0M
- Term loan drawn
- 2.0B
- Raythera upfront
- 225.0M
- Ocrevus royalty q3
- 369.9M
- Q3 2025 net income
- 466.5
- Zurzuvae q3 revenue
- 84.4M
- Nine month net income
- 396.4
- Q3 restructuring charges
- 66.5M
- Apellis cash consideration
- 5,406.0M
- Apellis total consideration
- 5,410.1M
- Alzheimers collab q3 revenue
- 68.4M
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.